Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1004723 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK1004726 (1000mg) | ACTIVE_COMPARATOR | 1000mg aqueous suspension |
| Placebo | PLACEBO_COMPARATOR | Intranasal spray |
| GSK1004723 (200mg) | ACTIVE_COMPARATOR | 200 mg aqueous suspension |
| Subjects receiving GSK1004723 + placebo in cohort I and II | EXPERIMENTAL | Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray. |
| Subjects receiving GSK1004723 200 micrograms in cohort III | EXPERIMENTAL | Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days. |
| Subjects receiving placebo in cohort III | EXPERIMENTAL | Eligible subjects will receive nasal spray of placebo given once daily for 14 days. |
| Subjects receiving GSK1004723 1000 micrograms in cohort IV | EXPERIMENTAL | Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days. |
| Subjects receiving placebo in cohort IV | EXPERIMENTAL | Eligible subjects will receive nasal spray of placebo given once daily for 14 days. |
| Name | Type | Description |
|---|---|---|
| GSK1004723 (200mg) | DRUG | Intranasal antihistamine. |
| Placebo | OTHER | Equivalent to GSK1004723 in presentation etc. |
| GSK1004723 (1000mg) | DRUG | Intranasal antihistamine. |
| GSK1004723 | DRUG | GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration. |
Inclusion Criteria: * Subject is healthy apart from seasonal allergic rhinitis, as determined by a physician. Can have mild asthma. * Male * Aged 18 - 65 * Weight 50kg+, BMI 19-32 kg/m2 * Exhibit response to Challenge Chamber and skin prick test. * Non-smoker * Capable of giving informed consent E...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
GSK1004723 is an investigational small molecule developed by GSK plc for allergic rhinitis and seasonal allergic rhinitis. It is an intranasal antagonist that targets both the HRH3 and HRH1 histamine receptors. It has been studied in Phase 1 and Phase 2 clinical trials and is not an approved product.
GSK1004723 is being studied for the treatment of allergic rhinitis, including seasonal allergic rhinitis. Clinical testing has focused on nasal allergen challenge models in adults, where the drug is given intranasally as a single dose to assess its effects on allergy symptoms.
GSK1004723 targets the HRH3 and HRH1 histamine receptors and acts as an antagonist at both. This dual H1 and H3 antagonism is the basis for its development as an intranasal treatment for allergic rhinitis, aiming to block histamine-driven nasal allergic responses.
GSK1004723 is developed by GSK plc, which trades under the ticker GSK. The compound, identified by the ChEMBL ID CHEMBL1767164, is part of the company's respiratory research portfolio and has been evaluated in company-sponsored clinical studies.
GSK1004723 has completed Phase 2 development. A Phase 2 allergen challenge chamber study in allergic rhinitis was completed, and an earlier Phase 1 first-time-in-human study was also completed. There are no active trials of GSK1004723, and it is not an approved medicine.
GSK1004723 has been studied in two completed trials. NCT00824356 was a Phase 2, randomized, double-blind, placebo-controlled allergen challenge chamber study of single-dose intranasal GSK1004723 in 54 men in Germany. NCT00694993 was a Phase 1 single and repeat dose first-time-in-human study in 19 healthy men.